^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FGFR2 overexpression

i
Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor
Entrez ID:
20d
Phase classification
|
KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
|
Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)
1m
Radiolabelled FGF-2 for Imaging Activated Fibroblasts in the Tumor Micro-Environment. (PubMed, Biomolecules)
we labeled FGF-2 with 99mTc and showed nanomolar Kd in vitro with human keratinocytes expressing FGF-2 receptors. In mice, 99mTc-FGF-2 rapidly and efficiently accumulated in tumors expressing FGF-2 receptors. This new radiopharmaceutical could be used in humans to image TAFs.
Journal
|
FGF2 (Fibroblast Growth Factor 2)
|
FGFR2 overexpression • FGFR overexpression
1m
Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2. (PubMed, Cell Death Dis)
In conclusion, CAFs inhibited ferroptosis to decrease DDP sensitivity in NPC through secreting FGF5 and activating downstream FGFR2/Nrf2 signaling. The therapeutic strategy targeting FGF5/FGFR2 axis from CAFs might augment DDP sensitivity, thus decreasing the side effects of DDP in NPC treatment.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 overexpression • FGFR2 expression
|
cisplatin
1m
Trial primary completion date • Combination therapy • Metastases
|
FGFR2 overexpression • FGFR2b overexpression
|
Opdivo (nivolumab) • capecitabine • oxaliplatin • bemarituzumab (AMG 552)
1m
New therapeutic target molecules for gastric and gastroesophageal junction cancer. (PubMed, Int J Clin Oncol)
Phase III and Ib/III trials of the FGFR2-targeted antibody bemarituzumab for G/GEJ cancer overexpressing FGFR2b are ongoing based on the promising result in a phase II trial, especially in cases with an FGFR2b positivity of ≥ 10%...CLDN18.2 is expressed in some G/GEJ tumors but lacks oncogenic driver potential, and the CLDN18.2-targeted antibody zolbetuximab prolonged the survival of CLDN18.2-positive G/GEJ cancer patients in phase III trials...Similarly, targeting of nondriver molecules such as DKK1, TROP2, and CEACAM5 is under investigation in early-stage clinical trials. This shift in focus from target molecules with driver potential to markers for precise drug delivery should increase the number of possible targets in G/GEJ cancer.
Review • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18) • CEACAM5 (CEA Cell Adhesion Molecule 5) • DKK1 (dickkopf WNT signaling pathway inhibitor 1)
|
FGFR2 amplification • CLDN18.2 positive • FGFR2 overexpression • FGFR2b overexpression
|
Vyloy (zolbetuximab) • bemarituzumab (AMG 552)
2ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
FGFR2 overexpression • FGFR2b overexpression
|
Opdivo (nivolumab) • capecitabine • oxaliplatin • bemarituzumab (AMG 552)
3ms
FGFR2 and miR-889-3p expression in oral cancer is associated with cervical lymph node metastasis. (PubMed, Oral Dis)
Decreased expression of miR-889-3p in OSCC tumours suggests that miR-889-3p functions as a tumour suppressor gene. Overexpression of FGFR2 further proves the role of miR-889-3p in the regulation of the FGFR2 pathway. This was further confirmed by showing differences in miR-889-3p expression in positive and negative LNM cases.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 overexpression • FGFR2 expression • FGFR2b expression
3ms
FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov)
P1/2, N=303, Recruiting, Amgen | Trial completion date: Jul 2026 --> Jun 2027 | Trial primary completion date: Oct 2024 --> Sep 2025
Trial completion date • Trial primary completion date • Pan tumor
|
FGFR2 overexpression • FGFR2b overexpression
|
bemarituzumab (AMG 552)
3ms
Alteration of chromosome structure impacts gene expressions implicated in pancreatic ductal adenocarcinoma cells. (PubMed, BMC Genomics)
Collectively, our findings reveal that the chromosomal conformational alterations, in addition to the well-known genetic mutations, are critical for PDAC tumorigenesis.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FOXA2 (Forkhead Box A2) • CPOX (Coproporphyrinogen Oxidase) • CYP2R1 (Cytochrome P450 Family 2 Subfamily R Member 1)
|
FGFR2 overexpression
3ms
Advances in targeted therapy for gastric cancer based on tumor driver genes. (PubMed, Zhejiang Da Xue Xue Bao Yi Xue Ban)
Among them, trastuzumab, as the first targeted drug for gastric cancer, effectively inhibits the proliferation and metastasis of tumor cells by targeting overexpressed HER2, and has become the standard treatment for HER2-positive gastric cancer patients. Ramucirumab, on the other hand, inhibits tumor angiogenesis by targeting VEGFR2 and has been used as second-line therapy for advanced gastric cancer patients. In addition, bemarituzumab targets overexpressed FGFR2, while zolbetuximab targets overexpressed CLDN18.2, significantly extending progression-free survival and overall survival in patients with gastric cancer in clinical trials. This article reviews the roles of tumor driver genes in the progression of gastric cancer; and the treatment strategies for gastric cancer based on targeting HER2, VEGF, FGFR2, CLDN18.2, MET and other tumor driver genes, aiming to provide reference for clinical application of targeted therapy for gastric cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18) • KDR (Kinase insert domain receptor)
|
HER-2 positive • HER-2 overexpression • CLDN18.2 expression • FGFR2 overexpression • CLDN18.2 overexpression • CLDN1 overexpression
|
Herceptin (trastuzumab) • Cyramza (ramucirumab) • Vyloy (zolbetuximab) • bemarituzumab (AMG 552)
4ms
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. (PubMed, Gastric Cancer)
In FGFR2b-positive advanced GC, the combination of bemarituzumab-mFOLFOX6 led to numerically longer median PFS and OS compared with mFOLFOX6 alone. Efficacy was more pronounced with FGFR2b overexpression in ≥ 10% of tumor cells. Confirmatory phase 3 trials are ongoing (NCT05052801, NCT05111626).
P2 data • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
HER-2 negative • FGFR2 overexpression • FGFR2b overexpression • FGFR2b positive
|
5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
5ms
Phase classification • Enrollment change • Combination therapy • Metastases
|
FGFR2 overexpression • FGFR2b overexpression
|
Opdivo (nivolumab) • capecitabine • oxaliplatin • bemarituzumab (AMG 552)
5ms
Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer. (PubMed, Biomedicines)
our findings suggest that concurrent amplification of FGFR2 and MET in GC patients is associated with clinical aggressiveness and may contribute to non-responsiveness to chemotherapy or targeted therapy.
Journal • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase) • FGFR2 (Fibroblast growth factor receptor 2)
|
MET amplification • FGFR2 amplification • FGFR2 overexpression
5ms
Phase classification • Pan tumor
|
FGFR2 overexpression • FGFR2b overexpression
|
bemarituzumab (AMG 552)
6ms
Efficacy and safety of nivolumab and CapeOX in patients with previously untreated FGFR2-positive, PD-L1-positive advanced gastric cancer: A single-arm, multicenter, phase 2 study NIVOFGFR2. (ASCO-GI 2024)
In this single-arm, multi-center, phase 2 study, eligible patients had metastatic untreated HER2-negative gastric adenocarcinoma with centrally confirmed expression of PD-L1 (CPS≥5; DAKO 28-8) and FGFR2 (moderate (2+) and strong (3+) membranous staining in more than 1% of tumor cells; Abсam EPR24075-418). Patients received nivolumab 360 mg with CapeOX (capecitabine and oxaliplatin) every 3 weeks... An interim analysis demonstrates modest efficacy and an acceptable safety profile of nivolumab in combination with chemotherapy in patients with FGFR2-positive, PD-L1-positive metastatic GC. Further follow-up is ongoing. 1.
Clinical • P2 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2)
|
PD-L1 expression • HER-2 negative • FGFR2 overexpression • FGFR2 expression
|
Opdivo (nivolumab) • capecitabine • oxaliplatin • crolibulin (EPC2407)
6ms
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. (PubMed, Sci Rep)
Per institutional and public databases, FGFR2 mutations and amplifications had a population frequency of 1.1%-2.6% and 1.5%-2.5%, respectively, in breast cancer patients. FGFR2 alterations in breast cancer may represent infrequent but highly promising targets for futibatinib.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR2 mutation • FGFR2 amplification • FGFR2 overexpression • FGFR1 expression • FGFR2 expression • FGFR3 Y375C • FGFR2 Y375C
|
Lytgobi (futibatinib)
8ms
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (clinicaltrials.gov)
P1b, N=180, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Apr 2024 | Trial primary completion date: Mar 2025 --> Apr 2024
Enrollment closed • Trial completion date • Trial primary completion date
|
KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
|
Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)
10ms
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (clinicaltrials.gov)
P1b, N=180, Recruiting, Amgen | Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
|
Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)
11ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
FGFR2 overexpression • FGFR2b overexpression
|
Opdivo (nivolumab) • capecitabine • oxaliplatin • bemarituzumab (AMG 552)
1year
Combination therapy • New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2)
|
HER-2 negative • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression
|
PD-L1 IHC 28-8 pharmDx
|
Opdivo (nivolumab) • capecitabine • oxaliplatin
1year
Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT) (ESMO-GI 2023)
After 24 months of follow-up, patients with FGFR2b overexpression treated with bemarituzumab + mFOLFOX6 continued to show clinically meaningful outcomes over patients treated with placebo + mFOLFOX6; more pronounced efficacy was observed in patients with ≥10% of tumor cells with 2+/3+ FGFR2b IHC staining intensity. Randomized phase 3 trials focused on patients with ≥10% of tumor cells to confirm the observed clinical benefit of bemarituzumab are ongoing.
Clinical • P2 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
HER-2 positive • FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression
|
5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
1year
Inhibition of FGFR2 Signaling by Cynaroside Attenuates Liver Fibrosis. (PubMed, Pharmaceuticals (Basel))
Animal experiments on a carbon tetrachloride (CCl) mouse model and a nonalcoholic steatohepatitis mouse model indicate that CYN treatment reduces liver fibrosis during fibrosis formation. These findings suggest that CYN prevents liver fibrosis formation at the cell level and in mouse models.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 overexpression • FGFR2 expression
1year
FGFR2 modulates ALK inhibition response in high-risk neuroblastoma (AACR 2023)
In vivo studies using patient-derived xenograft (PDX) models of high-risk NB (MYCN-amplified and ALKF1174L mutant) showed that combinations of either ponatinib or erdafitinib with lorlatinib decreased tumour growth and increased survival compared to PDXs treated with vehicle or either agent alone. In conclusion, these findings suggest that FGFR2 alters NB sensitivity to lorlatinib and modulation of this pathway in combination with ALK inhibition is a promising approach to improve NB treatment response and ultimately patient survival.
Late-breaking abstract
|
ALK (Anaplastic lymphoma kinase) • FGFR2 (Fibroblast growth factor receptor 2) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
FGFR2 mutation • MYCN amplification • FGFR2 overexpression • FGFR2 expression
|
Iclusig (ponatinib) • Lorbrena (lorlatinib) • Balversa (erdafitinib)
1year
Inhibition of HSF1 demonstrates therapeutic efficacy in preclinical models of cholangiocarcinoma (AACR 2023)
NXP800, a HSF1 inhibitor, demonstrated significant therapeutic activity in a cholangiocarcinoma PDX. Further studies are needed and being performed to determine the role of HSF1 inhibition in human cholangiocarcinoma.
Preclinical • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR1 (Fibroblast growth factor receptor 1) • AR (Androgen receptor) • ARID1A (AT-rich interaction domain 1A) • HSF1 (Heat Shock Transcription Factor 1)
|
NRAS mutation • ARID1A mutation • FGFR2 mutation • FGFR1 mutation • NRAS Q61 • AR overexpression • FGFR2 overexpression • AR expression • FGFR2 expression
|
NXP800
1year
FGFR2 upregulates PAI-1 via JAK2/STAT3 signaling to induce M2 polarization of macrophages in colorectal cancer. (PubMed, Biochim Biophys Acta Mol Basis Dis)
Moreover, the combination of a PAI-1 inhibitor and anti-PD-1 therapy exhibited superior antitumor activity in mice. These findings offer novel insights into the molecular mechanisms underlying tumor deterioration and provide potential therapeutic targets for CRC treatment.
Journal • PD(L)-1 Biomarker • IO biomarker
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 overexpression • FGFR2 expression • PAI1 expression
over1year
Trial completion date
|
KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
|
Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)
over1year
Prognostic significance for recurrence of FGFR2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection. (PubMed, Hepatol Res)
We demonstrated that FGFR2 high expression was the independent prognostic factor for recurrence of resected ICC.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • CD8 (cluster of differentiation 8)
|
FGFR2 fusion • FGFR fusion • FGFR2 overexpression • FGFR2 expression • FGFR2b expression
over1year
Enrollment change • Trial primary completion date
|
KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
|
Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • bemarituzumab (AMG 552)
over1year
Oesogastric cancer - new therapeutic targets (PubMed, Bull Cancer)
FGFR2 is overexpressed in one third of patients, and its targeting with a specific monoclonal antibody bemarituzumab showed a significant improvement in survival...The combination of zolbetuximab and chemotherapy provides a survival benefit, correlated with the intensity of CLDN 18.2 expression...Finally, with the recent advent of immunotherapy, one of the future challenges will be to optimize it through combination strategies with targeted therapies. The combination of anti-angiogenic and immunotherapy seems promising in gastric cancer.
Review • Journal • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 overexpression • FGFR2 overexpression • FGFR2 expression
|
Vyloy (zolbetuximab) • bemarituzumab (AMG 552)
over1year
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. (PubMed, Lancet Oncol)
In this exploratory phase 2 study, despite no statistically significant improvement in progression-free survival, treatment with bemarituzumab showed promising clinical efficacy. Confirmatory phase 3 trials of bemarituzumab plus mFOLFOX6 powered to demonstrate statistical significance are being investigated in patients with previously untreated, FGFR2b-overexpressing, advanced gastric or gastro-oesophageal junction adenocarcinoma.
P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
HER-2 negative • FGFR2 overexpression • FGFR2b overexpression • FGFR2b positive
|
5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
over1year
Circ_0008234 regulates the biological process of gallbladder carcinoma by targeting the miR-204-5p/FGFR2 axis. (PubMed, Histol Histopathol)
Circ_0008234 mediated GBC via the miR-204-5p/FGFR2 axis, providing a novel targeted therapy for gallbladder carcinoma.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • MIR204 (MicroRNA 204)
|
FGFR2 overexpression
over1year
Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC) (ESMO Asia 2022)
Adding bemarituzumab, a first-in-class, anti-FGFR2b monoclonal antibody to mFOLFOX6 improved outcomes, indicating FGFR2b as a promising therapeutic target...FGFR2b overlap with PD-L1 is shown in the table. Table: 384P Conclusions Over 20% of sqNSCLC tissue samples overexpress FGFR2b, making it a promising therapeutic target for agents such as bemarituzumab.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • FPR2 (Formyl Peptide Receptor 2)
|
PD-L1 expression • FGFR2 overexpression • FGFR2b overexpression
|
PD-L1 IHC 22C3 pharmDx
|
5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
over1year
FORTITUDE-101: Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov)
P3, N=516, Recruiting, Amgen | Trial completion date: Jan 2025 --> Aug 2025 | Trial primary completion date: Jan 2025 --> Aug 2025
Trial completion date • Trial primary completion date
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 overexpression • FGFR2b overexpression
|
5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
almost2years
Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma (PubMed, Beijing Da Xue Xue Bao Yi Xue Ban)
Our work sheds light on the potential role of FGFR2 in the development of ccRCC, suggesting that FGFR2 may serve as a prognostic marker and potential therapeutic target for patients with ccRCC.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 overexpression • FGFR2 expression • FGFR2b expression
almost2years
FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer. (PubMed, Mol Oncol)
In vitro analyses showed that FGF7/FGFR2 signalling: (a) abolished the effect of P4 on E2-promoted 3D cell growth and response to tamoxifen; (b) regulated ER and PR expression and activity; (c) increased formation of ER-PR complexes; and (d) reversed P4-triggered deregulation of ER-dependent genes. Our results demonstrate for the first time that the FGF7/FGFR2-JunB axis abolishes the modulatory effects of PR on ER-associated biological functions in premenopausal ER+ BCa. This may provide foundations for a better selection of patients for FGFR-targeting therapeutic strategies.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • FGFR2 (Fibroblast growth factor receptor 2) • FGF7 (Fibroblast Growth Factor 7) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)
|
ER positive • FGFR2 overexpression • FGFR2 expression • FGFR2b expression • PGR expression
|
tamoxifen
almost2years
Trial completion
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression
|
5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)
almost2years
New P3 trial
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 overexpression • FGFR2b overexpression
|
Opdivo (nivolumab) • bemarituzumab (AMG 552)
almost2years
Trial primary completion date
|
KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
|
docetaxel • bemarituzumab (AMG 552)
almost2years
Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients. (PubMed, J Clin Med)
Our study suggested that FGFR2 expression can be used to classify HCC patients based on HCV infection. This FGFR2-based classification may lead to new therapeutic strategies against HCV-positive HCC subtypes.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR2 overexpression • FGFR1 expression • FGFR2 expression • FGFR2b expression • FGFR3 expression
2years
Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway. (PubMed, Oncogene)
In conclusion, SOX9 and FGF7 were prognostic biomarkers of CCA. WNT3A-TCF7-SOX9 axis could induce pemigatinib resistance in two independent pathways: (1)SOX9 directly promotes FGFR2 transcription and expression; (2)SOX9 elevates FGF7 expression, which could be secreted from CCA cells and activates FGFR2 phosphorylation in an autocrine pathway.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • SOX9 (SRY-Box Transcription Factor 9) • FGF7 (Fibroblast Growth Factor 7) • TCF7 (Transcription Factor 7)
|
FGFR2 overexpression • SOX9 expression
|
Pemazyre (pemigatinib)
2years
Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients. (PubMed, Cancer Diagn Progn)
HER2-positive GC patients, without overexpression of FGFR2, exhibited an improved prognosis and response rate to trastuzumab combination chemotherapy. Assessment of intra-tumoral FGFR2 expression could be helpful in predicting the prognosis and response to trastuzumab in HER2-positive GC patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
HER-2 positive • HER-2 overexpression • HER-2 expression • EGFR positive • FGFR2 overexpression • FGFR2 expression • FGFR2b expression
|
Herceptin (trastuzumab)
2years
FORTITUDE-201: A Study of Bemarituzumab Monotherapy and Docetaxel Combination in Participants With Squamous Non-small-cell Lung Cancer (SqNSCLC) With Fibroblast Growth Factor Receptor Isoform 2b (FGFR2b) Overexpression (clinicaltrials.gov)
P1b, N=108, Recruiting, Amgen | Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Jul 2025 | Trial primary completion date: Feb 2024 --> Jul 2024
Enrollment open • Trial completion date • Trial primary completion date
|
KRAS (KRAS proto-oncogene GTPase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
KRAS mutation • KRAS G12C • KRAS G12 • FGFR2 overexpression • FGFR2b overexpression
|
docetaxel • bemarituzumab (AMG 552)